Vita Life Sciences Beheer

Beheer criteriumcontroles 3/4

De CEO Vita Life Sciences is Andrew O'Keefe, benoemd in Jan2017, heeft een ambtstermijn van 7.83 jaar. De totale jaarlijkse vergoeding van { bedraagt A$ 886.73K, bestaande uit 49.8% salaris en 50.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.58% van de aandelen van het bedrijf, ter waarde A$ 1.87M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.7 jaar en 5 jaar.

Belangrijke informatie

Andrew O'Keefe

Algemeen directeur

AU$886.7k

Totale compensatie

Percentage CEO-salaris	49.8%
Dienstverband CEO	7.8yrs
Eigendom CEO	1.6%
Management gemiddelde ambtstermijn	7.7yrs
Gemiddelde ambtstermijn bestuur	5yrs

Recente managementupdates

Recent updates

Vita Life Sciences Limited (ASX:VLS) Looks Inexpensive But Perhaps Not Attractive Enough

Sep 23

Vita Life Sciences (ASX:VLS) Has Announced A Dividend Of A$0.035

Aug 28

Vita Life Sciences Limited (ASX:VLS) Stock Catapults 26% Though Its Price And Business Still Lag The Market

Mar 22

Vita Life Sciences (ASX:VLS) Has Announced That It Will Be Increasing Its Dividend To A$0.06

Mar 14

Vita Life Sciences' (ASX:VLS) Shareholders Will Receive A Bigger Dividend Than Last Year

Feb 28

A Look At The Fair Value Of Vita Life Sciences Limited (ASX:VLS)

Dec 20

Should You Be Adding Vita Life Sciences (ASX:VLS) To Your Watchlist Today?

Aug 24

If You Like EPS Growth Then Check Out Vita Life Sciences (ASX:VLS) Before It's Too Late

May 14

Did Vita Life Sciences' (ASX:VLS) Share Price Deserve to Gain 83%?

Mar 18

Vita Life Sciences Limited (ASX:VLS) On An Uptrend: Could Fundamentals Be Driving The Stock?

Feb 17

Vita Life Sciences (ASX:VLS) Is Growing Earnings But Are They A Good Guide?

Jan 20

Here's Why We Think Vita Life Sciences (ASX:VLS) Is Well Worth Watching

Dec 22

Vita Life Sciences Limited's (ASX:VLS) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Nov 19

Vita Life Sciences Limited's (ASX:VLS) Prospects Need A Boost To Lift Shares

Jul 14

Analyse CEO-vergoeding

Hoe is Andrew O'Keefe's beloning veranderd ten opzichte van Vita Life Sciences's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	AU$9m
Mar 31 2024	n/a	n/a	AU$9m
Dec 31 2023	AU$887k	AU$442k	AU$9m
Sep 30 2023	n/a	n/a	AU$8m
Jun 30 2023	n/a	n/a	AU$7m
Mar 31 2023	n/a	n/a	AU$7m
Dec 31 2022	AU$984k	AU$438k	AU$7m
Sep 30 2022	n/a	n/a	AU$8m
Jun 30 2022	n/a	n/a	AU$8m
Mar 31 2022	n/a	n/a	AU$8m
Dec 31 2021	AU$653k	AU$442k	AU$8m
Sep 30 2021	n/a	n/a	AU$8m
Jun 30 2021	n/a	n/a	AU$7m
Mar 31 2021	n/a	n/a	AU$6m
Dec 31 2020	AU$510k	AU$440k	AU$6m
Sep 30 2020	n/a	n/a	AU$6m
Jun 30 2020	n/a	n/a	AU$5m
Mar 31 2020	n/a	n/a	AU$4m
Dec 31 2019	AU$535k	AU$442k	AU$3m
Sep 30 2019	n/a	n/a	AU$2m
Jun 30 2019	n/a	n/a	AU$2m
Mar 31 2019	n/a	n/a	AU$2m
Dec 31 2018	AU$424k	AU$421k	AU$2m
Sep 30 2018	n/a	n/a	AU$3m
Jun 30 2018	n/a	n/a	AU$4m
Mar 31 2018	n/a	n/a	AU$3m
Dec 31 2017	AU$445k	AU$408k	AU$3m

Compensatie versus markt: De totale vergoeding ($USD 581.27K ) Andrew } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 299.27K ).

Compensatie versus inkomsten: De vergoeding van Andrew is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Andrew O'Keefe

7.8yrs

Tenure

AU$886,732

Compensatie

Mr. Andrew W. O'Keefe has been Managing Director and Director of Vita Life Sciences Limited since January 1, 2017. Mr. O'Keefe served as Acting Managing Director of Vita Life Sciences Limited since October...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Andrew O'Keefe	MD & Director	7.8yrs	AU$886.73k	1.58% A$ 1.9m
Chin Khoo	CFO & Company Secretary	7.5yrs	AU$365.80k	0.99% A$ 1.2m
Melissa Pereira	Group Marketing Manager	7.8yrs	AU$175.02k	0.31% A$ 367.4k
Shaun Rutherford	Chief Executive Officer of Australia	no data	AU$521.94k	0.93% A$ 1.1m
K. Beh	Chief Executive Officer of Vita Life Sciences Malaysia & Singapore	5.3yrs	AU$545.55k	1.07% A$ 1.3m
June Lau	General Manager of Operations & Business Support	no data	geen gegevens	geen gegevens
Alexandra Ward	Technical & NPD Manager	no data	geen gegevens	geen gegevens

7.7yrs

Gemiddelde duur

Ervaren management: Het managementteam van VLS is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.7 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Andrew O'Keefe	MD & Director	7.8yrs	AU$886.73k	1.58% A$ 1.9m
Henry Townsing	Non-Executive Chairman	12.9yrs	AU$136.90k	0.77% A$ 907.6k
Peter Osborne	Independent Non-Executive Director	1.3yrs	AU$16.67k	0.045% A$ 53.1k
Jack Teoh	Non-Executive Director	2.2yrs	AU$37.21k	geen gegevens

5.0yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van VLS wordt beschouwd als ervaren (gemiddelde ambtstermijn 5 jaar).

Vita Life Sciences Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Non-Executive Chairman recently sold AU$654k worth of stock

MD & Director recently sold AU$1.9m worth of stock

Vita Life Sciences Limited, Annual General Meeting, May 15, 2024

Vita Life Sciences Limited Appoints Peter Osborne as an Independent Non-Executive Director

No independent directors

No independent directors

Recent updates

New minor risk - Shareholder dilution

Vita Life Sciences Limited (ASX:VLS) Looks Inexpensive But Perhaps Not Attractive Enough

Upcoming dividend of AU$0.035 per share

First half 2024 earnings released: EPS: AU$0.078 (vs AU$0.074 in 1H 2023)

Vita Life Sciences (ASX:VLS) Has Announced A Dividend Of A$0.035

First half dividend increased to AU$0.035

Now 22% undervalued

Non-Executive Chairman recently sold AU$654k worth of stock

New minor risk - Insider selling

MD & Director recently sold AU$1.9m worth of stock

Vita Life Sciences Limited (ASX:VLS) Stock Catapults 26% Though Its Price And Business Still Lag The Market

Upcoming dividend of AU$0.06 per share

Vita Life Sciences (ASX:VLS) Has Announced That It Will Be Increasing Its Dividend To A$0.06

Vita Life Sciences Limited, Annual General Meeting, May 15, 2024

Vita Life Sciences' (ASX:VLS) Shareholders Will Receive A Bigger Dividend Than Last Year

Final dividend increased to AU$0.06

Full year 2023 earnings released: EPS: AU$0.17 (vs AU$0.13 in FY 2022)

New minor risk - Insider selling

Vita Life Sciences Limited Provides Earnings Guidance for the Full Year Ending December 31, 2023

Upcoming dividend of AU$0.03 per share at 3.7% yield

First half 2023 earnings released: EPS: AU$0.074 (vs AU$0.069 in 1H 2022)

Vita Life Sciences Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, 6 October 2023

Vita Life Sciences Limited Appoints Peter Osborne as an Independent Non-Executive Director

Investor sentiment improves as stock rises 15%

Upcoming dividend of AU$0.033 per share at 3.9% yield

Full year 2022 earnings released: EPS: AU$0.13 (vs AU$0.16 in FY 2021)

No independent directors

A Look At The Fair Value Of Vita Life Sciences Limited (ASX:VLS)

Vita Life Sciences Provides Earnings Guidance for the Full Year Ending 31 December 2022

No independent directors

Vita Life Sciences Limited Announces Board Changes, Effective 30 September 2022

Upcoming dividend of AU$0.028 per share

Vita Life Sciences Limited Declares Fully Franked Interim Dividend for the Six Months Ended June 30, 2022, Payable on 7 October 2022

First half 2022 earnings released: EPS: AU$0.069 (vs AU$0.07 in 1H 2021)

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2022

Non-Executive Chairman exercised options to buy AU$433k worth of stock.

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Upcoming dividend of AU$0.03 per share

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Vita Life Sciences Limited Announces Dividend for Six Months Ended December 31, 2021, Payable on April 7, 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Upcoming dividend of AU$0.028 per share

Should You Be Adding Vita Life Sciences (ASX:VLS) To Your Watchlist Today?

First half 2021 earnings released: EPS AU$0.07 (vs AU$0.058 in 1H 2020)

Independent Non-Executive Director Jonathan Tooth has left the company

Investor sentiment improved over the past week

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2021

If You Like EPS Growth Then Check Out Vita Life Sciences (ASX:VLS) Before It's Too Late

Full year 2020 earnings released: EPS AU$0.12 (vs AU$0.057 in FY 2019)

Did Vita Life Sciences' (ASX:VLS) Share Price Deserve to Gain 83%?

Investor sentiment improved over the past week

Upcoming Dividend of AU$0.028 Per Share

Full year 2020 earnings released: EPS AU$0.12 (vs AU$0.057 in FY 2019)

Vita Life Sciences Limited (ASX:VLS) On An Uptrend: Could Fundamentals Be Driving The Stock?

Vita Life Sciences (ASX:VLS) Is Growing Earnings But Are They A Good Guide?

Here's Why We Think Vita Life Sciences (ASX:VLS) Is Well Worth Watching

New 90-day high: AU$1.00

Vita Life Sciences Limited's (ASX:VLS) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Upcoming Dividend of AU$0.015 Per Share

New 90-day high - AU$0.95

First half earnings released

New 90-day high - AU$0.70

Vita Life Sciences Limited's (ASX:VLS) Prospects Need A Boost To Lift Shares

Analyse CEO-vergoeding

CEO

Tenure

Compensatie